448 related articles for article (PubMed ID: 19261295)
1. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.
Levy HL; Milanowski A; Chakrapani A; Cleary M; Lee P; Trefz FK; Whitley CB; Feillet F; Feigenbaum AS; Bebchuk JD; Christ-Schmidt H; Dorenbaum A;
Lancet; 2007 Aug; 370(9586):504-10. PubMed ID: 17693179
[TBL] [Abstract][Full Text] [Related]
3. Sapropterin: a new therapeutic agent for phenylketonuria.
Hegge KA; Horning KK; Peitz GJ; Hegge K
Ann Pharmacother; 2009 Sep; 43(9):1466-73. PubMed ID: 19654333
[TBL] [Abstract][Full Text] [Related]
4. Is sapropterin treatment suitable for all subjects with phenylketonuria?
Doggrell SA
Expert Opin Pharmacother; 2008 Jan; 9(1):145-7. PubMed ID: 18076346
[TBL] [Abstract][Full Text] [Related]
5. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
[TBL] [Abstract][Full Text] [Related]
6. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
Sanford M; Keating GM
Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
[TBL] [Abstract][Full Text] [Related]
8. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
Blau N
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
[TBL] [Abstract][Full Text] [Related]
9. Sapropterin. Phenylketonuria: for a minority of patients.
Prescrire Int; 2010 Jun; 19(107):101-4. PubMed ID: 20738029
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.
Lee P; Treacy EP; Crombez E; Wasserstein M; Waber L; Wolff J; Wendel U; Dorenbaum A; Bebchuk J; Christ-Schmidt H; Seashore M; Giovannini M; Burton BK; Morris AA;
Am J Med Genet A; 2008 Nov; 146A(22):2851-9. PubMed ID: 18932221
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
[TBL] [Abstract][Full Text] [Related]
12. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria.
Trefz FK; Blau N
Pediatrics; 2003 Dec; 112(6 Pt 2):1566-9. PubMed ID: 14654666
[TBL] [Abstract][Full Text] [Related]
13. Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride.
Stockler-Ipsiroglu S; Yuskiv N; Salvarinova R; Apatean D; Ho G; Cheng B; Giezen A; Lillquist Y; Ueda K
Mol Genet Metab; 2015 Mar; 114(3):409-14. PubMed ID: 25497838
[TBL] [Abstract][Full Text] [Related]
14. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria.
Burton B; Grant M; Feigenbaum A; Singh R; Hendren R; Siriwardena K; Phillips J; Sanchez-Valle A; Waisbren S; Gillis J; Prasad S; Merilainen M; Lang W; Zhang C; Yu S; Stahl S
Mol Genet Metab; 2015 Mar; 114(3):415-24. PubMed ID: 25533024
[TBL] [Abstract][Full Text] [Related]
16. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
Burton BK; Grange DK; Milanowski A; Vockley G; Feillet F; Crombez EA; Abadie V; Harding CO; Cederbaum S; Dobbelaere D; Smith A; Dorenbaum A
J Inherit Metab Dis; 2007 Oct; 30(5):700-7. PubMed ID: 17846916
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the use of sapropterin in phenylketonuria.
Cunningham A; Bausell H; Brown M; Chapman M; DeFouw K; Ernst S; McClure J; McCune H; O'Steen D; Pender A; Skrabal J; Wessel A; Jurecki E; Shediac R; Prasad S; Gillis J; Cederbaum S
Mol Genet Metab; 2012 Jul; 106(3):269-76. PubMed ID: 22575621
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of sapropterin: the PKUDOS registry experience.
Longo N; Arnold GL; Pridjian G; Enns GM; Ficicioglu C; Parker S; Cohen-Pfeffer JL;
Mol Genet Metab; 2015 Apr; 114(4):557-63. PubMed ID: 25724073
[TBL] [Abstract][Full Text] [Related]
19. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.
Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N
Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284
[TBL] [Abstract][Full Text] [Related]
20. Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR; Merrin M
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008005. PubMed ID: 25812600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
